Insiders · NBP

Wei Fu

Director at NovaBridge Biosciences (NBP) since March 2026

Wei Fu has filed 2 insider reports with the SEC since March 2026, as director at NovaBridge Biosciences (NBP). The latest filing, on June 30, 2026, reports grant or award at NovaBridge Biosciences (NBP).

Filings
2
Companies
1
Bought on market
None
Sold on market
None

Companies where Wei Fu is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
NovaBridge Biosciences logo
NBP
NovaBridge Biosciences
Directorsince March 2026$0.83Jun 30, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Wei Fu with

Other insiders at the same companies

Questions about Wei Fu

What is Wei Fu's role at NovaBridge Biosciences?
Wei Fu reports to the SEC as director at NovaBridge Biosciences (NBP), according to the latest filing on June 30, 2026.
Has Wei Fu bought or sold stock recently?
No open-market purchases or sales by Wei Fu are on file. The filings report grant or award.
How do I get alerts when Wei Fu files?
Follow Wei Fu on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Wei Fu (SEC CIK 0001885756). Totals count each trade once, skipping amendments whose original is on file, from Mar 19, 2026 on. View on SEC EDGAR · Get this as JSON